

TABLE OF CONTENTS

	PAGE
Abbreviations.....	1
1 Introduction.....	4
1.1 Components, classification and cost of pain.....	4
1.1.1 Components of pain.....	4
1.1.2 Classification of pain.....	5
1.1.2.1 Adaptive pain.....	5
1.1.2.2 Maladaptive pain.....	6
1.1.3 Cost of pain.....	6
1.2 Nociception.....	8
1.3 Chronic pain.....	9
1.3.1 Neuropathic pain.....	9
1.3.2 Inflammatory pain.....	10
1.3.3 Mechanism for chronic pain.....	11
1.3.3.1 Peripheral sensitization.....	12
1.3.3.2 Central sensitization.....	13
1.3.3.3 Long term depression of inhibition.....	14
1.3.3.4 Neuro-glial interactions.....	15
1.4 Neuronal plasticity and chronic pain.....	16
1.4.1 Biochemical profile changes.....	17
1.4.2 Functional plasticity.....	18
1.4.3 Structural plasticity.....	18
1.5 Dendritic spine morphogenesis.....	19
1.5.1 Molecular candidates in modulating spine morphogenesis.....	20
1.5.1.1 Ion channels.....	21
1.5.1.2 Kinases.....	22
1.5.1.3 Structural protein.....	22
1.5.1.4 Small G-protein family.....	23
1.5.1.5 Guanine-nucleotide exchange factor, GEF.....	25
1.6 Kal7.....	27
1.7 Multiple sclerosis.....	29
1.7.1 Types of MS.....	30
1.7.2 Cause of MS.....	30
1.7.3 Pathological evidence and putative mechanisms.....	31
1.7.4 Clinical manifestation and MS-related pain.....	32
1.8 EAE, an animal model for MS.....	33
1.8.1 Pain in EAE.....	33
1.9 Aims of this doctoral thesis.....	35
 2 Materials and Methods.....	 37
2.1 Materials.....	37
2.1.1 Chemicals and reagents.....	37
2.1.2 Nucleic acid and protein size standards.....	39

2.1.3 Enzymes.....	39
2.1.4 Commercial kits.....	39
2.1.5 Technical equipment.....	40
2.1.6 Analytical software	40
2.1.7 Oligonucleotides.....	41
2.1.8 List for antibodies.....	41
2.1.9 List for peptides.....	42
2.1.10 Buffers and solutions.....	42
2.1.11 Consumables.....	43
2.1.12 Animals.....	44
2.2 Methods.....	44
2.2.1 Bioinformatic analysis.....	44
2.2.1.1 Gene analysis of kalrn gene and RT-PCR strategy.....	44
2.2.2 Molecular biology analysis.....	45
2.2.2.1 Total RNA isolation.....	45
2.2.2.2 Reverse transcription (RT).....	46
2.2.2.3 Polymerase chain reaction (PCR) amplification.....	46
2.2.2.4 Molecular cloning.....	47
2.2.2.5 Transformation of chemical competent bacterial cells.....	47
2.2.2.6 Plasmid DNA preparation.....	47
2.2.2.7 Purification of DNA.....	48
2.2.2.8 Precipitation of nucleic acid.....	48
2.2.2.9 Restriction digestion.....	48
2.2.2.10 DNA-agarose gel electrophoresis.....	48
2.2.2.11 Quantitative Real-Time PCR.....	49
2.2.3 Protein biochemistry.....	49
2.2.3.1 Protein isolation.....	49
2.2.3.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE).....	50
2.2.3.3 Immunoblot.....	50
2.2.4 Histology.....	51
2.2.4.1 Tissue preparation for histology studies.....	51
2.2.4.2 Chromogenic immunohistochemistry.....	52
2.2.4.3 Immunofluorescence.....	52
2.2.4.4 Immunocytochemistry.....	53
2.2.5 Animal work.....	54
2.2.5.1 Animal handling.....	54
2.2.5.2 Spinal cord injection.....	54
2.2.5.3 Induction of EAE via active immunization.....	55
2.2.5.4 Monitoring of EAE development.....	56
2.2.5.5 Nociceptive testing.....	56
2.2.6 Electrophysiology.....	57
2.2.6.1 Spinal cord slice preparation and patch-clamp recordings.....	57
2.2.6.2 Afferent recordings in skin-nerve preparation.....	58
2.2.7 Morphological analysis and imaging.....	59

2.2.7.1 Golgi staining.....	59
2.2.7.2 Confocal imaging and densitometry.....	60
2.2.8 Cell culture work.....	61
2.2.8.1 Primary spinal neuron preparation.....	61
2.2.9 Statistics.....	62
3 Results.....	63
3.1 Analysis of Kaiirin expression in the mouse spinal cord.....	63
3.1.1 Gene structure of <i>Kalm</i>	63
3.1.2 Basal expression of spinal Kalirin isoforms at mRNA and protein level..	64
3.1.2.1 Kaiirin mRNA transcripts expression in the mouse spinal cord.....	64
3.1.2.2 Expression of particular kalirin isoforms as determined by 3' RACE...	66
3.1.2.3 Kal7 is expressed in neuronal population in the spinal cord in culture.	67
3.1.2.4 Kalirin protein expression in the dorsal horn from the naive mouse spinal cord.....	68
3.1.3 Distribution of Kalirins in the naive mouse spinal cord.....	69
3.2 Conditional knockout of Kalirin in the mouse lumbar spinal cord.....	70
3.2.1 Strategy for Kalrn gene knockout.....	70
3.2.2 Spinal delivery of AAV virus, validation and optimization.....	70
3.2.2.1 Spinal injection of the AAV results in faithful and robust expression of gene of interest in neuronal cell population.....	70
3.2.2.2 Viral expression distribution, quantification and optimization.....	71
3.2.3 Expression of Cre recombinase within mouse spinal dorsal horn and characterization.....	73
3.2.3.1 Microinjection of Cre-expressing AAV virus led to selective gene manipulations.....	73
3.2.3.2 AAV-Cre successfully targeted most of the spinal dorsal horn neurons in the nociceptive laminae.....	73
3.2.4 Spinal Knockout of kalirin via microinjection of AAV-Cre.....	75
3.3 Effects of Kalirin on pain-related behavior.....	76
3.3.1 Effects of Kalirin on the maintenance of formalin-induced nocifensive behavior.....	77
3.3.2 Effects of Kalirin on the maintenance of chronic inflammation-related pain behavior.....	79
3.3.2.1 Effects of spinal knockout of total Kalirins on the development /maintenance of mechanical hypersensitivity induced by intraplantar CFA injection.....	80
3.3.2.2 Deletion of total Kalirin did not affect CFA-induced thermal hypersensitivity.....	80
3.3.2.3 Effects of spinal knockout of Kal7 on the development/maintenance of mechanical hypersensitivity induced by intraplantar CFA injection.....	81
3.3.2.4 Absence of Kal7 did not affect CFA-induced thermal hypersensitivity as compared to control group.....	82
3.4 Effects of Kalirin on neuronal spine morphogenesis.....	83

3.4.1 Spinal-neuron-specific deletion of Kal7 suppressed spine morphogenesis resulting from peripheral inflammatory insult.....	84
3.4.2 Conditional knockout of Kaiirin reduced the density of spine-like structures in cultured spinal neurons.....	85
3.5 Physiological and behavioral consequences of transient interruption of Kal7 signaling.....	87
3.5.1 Kal7-signaling-related electrophysiological properties in spino-PAG neuron.....	87
3.5.1.1 Kal7 C terminus (CT) peptide blocked LFS-induced spinal LTP in spino-PAG lamina I neurons.....	88
3.5.1.2 Kal7 interfering peptide did not affect the basic membrane properties of the spino-PAG lamina I neuron.....	89
3.5.2 Physiological significance of transient block of Kal7-mediated signaling in the spinal cord.....	90
3.5.2.1 Trying to understand the role of Kal7 signaling during development of CFA-induced mechanical hypersensitivity.....	91
3.5.2.2 Kal7 transient blockade did not exert effect over CFA-induced thermal hypersensitivity.....	91
3.6 Effects of Rac1 over pain-related behavior.....	93
3.6.1 Genetic manipulation of Rac1 expression within the spinal dorsal horn.....	93
3.6.2 Alterations in Rac1 expression and formalin-induced acute nocifensive behavior.....	94
3.6.2.1 Absence of Rac1 reduced second phase of formalin-induced nocifensive behavior.....	94
3.6.2.2 Overexpression of Rac1 exaggerated second phase of formalin-induced nocifensive behavior.....	94
3.6.3 Role of spinal Rac1 in the development of inflammatory pain behavior.....	95
3.6.3.1 Absence of Rac1 reduced the CFA-induced mechanical hypersensitivity.....	96
3.6.3.2 Absence of Rac1 did not affect the CFA-induced thermal hypersensitivity.....	96
3.6.3.3 Overexpression of Rac1 altered the basal threshold of mechanical perception but did not enhance the CFA-induced mechanical hypersensitivity	97
3.6.3.4 Overexpression of Rac1 has no effect on CFA-induced thermal hypersensitivity.....	98
3.7 Effect of Rac1 on spine morphogenesis in dorsal spinal neurons....	99
3.7.1 Spinal-deletion of Rac1 reduced spine formation in vivo.....	99
3.7.2 Spinal-overexpression of Rac1 increased dendritic spine formation...	100
3.8 Immunization and behavioral analysis in different EAE mouse models	101
3.8.1 Induction of EAE via active immunization in C57BL6 and SJL mice....	102
3.8.2 Analysis of pain behavior and general locomotion.....	103
3.8.2.1 Pain behavior in SJL-EAE and C57-EAE mice.....	103

3.8.2.2 General locomotion in EAE animals.....106

3.9 Characterization of the sensory abnormalities in PNS in SJL-EAE animals.....108

3.9.1 Electrophysiological analysis of peripheral nerve activity in SJL-EAE mice.....108

3.9.2 Immunohistological analysis of the central terminals patterning of primary afferents in the spinal cord of SJL-EAE mice.....110

3.10 Characterization of the spinal cord pathology in SJL-EAE animals112

3.10.1 Verification of IB4-positive cells in the spinal dorsal horn.....112

3.10.2 Analysis of the loss of NeuN-positive signals in the spinal cord.....113

3.10.3 Glia cells activation in spinal cord during EAE disease.....116

3.10.3.1 Immunohistochemical analysis of spinal glia activation in SJL-EAE mice.....116

3.10.3.2 Quantification of activated glia cells in the superficial dorsal horn in SJL-EAE and C57-EAE mice.....117

4 Discussion.....122

4.1 Possible activators for Kal7 during chronic pain.....122

4.2 Are NR2B-containing NMDARs upstream of Kal7 in modulation of pain?.....127

4.3 Kal7, Rac1 Dendritic spines and chronic pain.....131

4.4 Rac1 vs. RhoG.....132

4.5 Pain in MS and EAE.....134

4.6 Reduction of NeuN-positive cells in the spinal cord in EAE.....137

4.7 Neuronal-glia interaction in EAE.....138

4.8 Peripheral nerve alteration/ demyelination.....141

4.9 Outlook.....143

5 Summary.....144

6 Reference.....146

7 Publications.....166

8 Curriculum vitae.....167

9 Acknowledgement.....168